CY1124552T1 - Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 - Google Patents
Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4Info
- Publication number
- CY1124552T1 CY1124552T1 CY20211100874T CY211100874T CY1124552T1 CY 1124552 T1 CY1124552 T1 CY 1124552T1 CY 20211100874 T CY20211100874 T CY 20211100874T CY 211100874 T CY211100874 T CY 211100874T CY 1124552 T1 CY1124552 T1 CY 1124552T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzothiophenies
- thienopyridines
- compounds
- irak4 inhibitors
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762504956P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/031945 WO2018209012A1 (en) | 2017-05-11 | 2018-05-10 | Thienopyridines and benzothiophenes useful as irak4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124552T1 true CY1124552T1 (el) | 2022-07-22 |
Family
ID=62245511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100874T CY1124552T1 (el) | 2017-05-11 | 2021-10-07 | Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 |
Country Status (29)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| TW202115086A (zh) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk抑制劑 |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP3999508B1 (en) | 2019-07-18 | 2023-08-30 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021011727A1 (en) | 2019-07-18 | 2021-01-21 | Bristol-Myers Squibb Company | PYRAZOLO[3,4-d]PYRROLO[1,2-b]PYRIDAZINYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS |
| US12304916B2 (en) | 2019-07-23 | 2025-05-20 | Bristol-Myers Squibb Company | Thienopyridinyl and thiazolopyridinyl compounds useful as IRAK4 inhibitors |
| WO2021026181A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| ES3059914T3 (en) | 2019-08-13 | 2026-03-24 | Bristol Myers Squibb Co | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| CN111285844B (zh) * | 2020-02-24 | 2022-08-12 | 河南师范大学 | 具有生物活性的苯并噻吩取代酰胺类化合物及其合成方法和应用 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8627698D0 (en) * | 1986-11-20 | 1986-12-17 | Boots Co Plc | Therapeutic agents |
| CA2450769A1 (en) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| EP1518855B1 (en) | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| WO2005007646A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| EP1863571A1 (en) | 2005-03-09 | 2007-12-12 | Shering Corporation | Compounds for inhibiting ksp kinesin activity |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| JP2009526761A (ja) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| KR20100020454A (ko) | 2007-06-08 | 2010-02-22 | 바이엘 크롭사이언스 소시에떼아노님 | 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| JP5254693B2 (ja) | 2008-07-30 | 2013-08-07 | 三菱重工業株式会社 | Ｎｉ基合金用溶接材料 |
| EP2361902A4 (en) | 2008-11-21 | 2012-04-25 | Astellas Pharma Inc | 4,6-DIAMINONICOTINSÄUREAMIDVERBINDUNG |
| WO2010061971A1 (ja) | 2008-11-28 | 2010-06-03 | 興和株式会社 | ピリジン－３－カルボキシアミド誘導体 |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| AU2010289353B2 (en) | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
| JP2014515029A (ja) | 2011-04-29 | 2014-06-26 | アイカーン・スクール・オブ・メディシン・アト・マウント・シナイ | キナーゼ阻害剤 |
| CN104169275B (zh) | 2012-01-13 | 2017-06-09 | 百时美施贵宝公司 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
| ES2575604T3 (es) | 2012-01-13 | 2016-06-29 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa |
| EP2802576B1 (en) * | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| BR112015009850A2 (pt) | 2012-11-08 | 2017-07-11 | Bristol Myers Squibb Co | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase |
| KR102233252B1 (ko) | 2012-11-08 | 2021-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물 |
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| DK3126330T3 (en) | 2014-04-04 | 2019-04-23 | Pfizer | BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS |
| US10155765B2 (en) * | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| WO2016144849A1 (en) * | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Thienopyrazine inhibitors of irak4 activity |
| ES2822956T3 (es) | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| EP3313840B1 (en) | 2015-06-24 | 2019-07-24 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| HUE053705T2 (hu) | 2015-08-27 | 2021-07-28 | Pfizer | Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként |
-
2018
- 2018-05-10 PT PT187275896T patent/PT3621960T/pt unknown
- 2018-05-10 HU HUE18727589A patent/HUE056493T2/hu unknown
- 2018-05-10 MX MX2019012929A patent/MX2019012929A/es unknown
- 2018-05-10 EP EP18727589.6A patent/EP3621960B1/en active Active
- 2018-05-10 LT LTEPPCT/US2018/031945T patent/LT3621960T/lt unknown
- 2018-05-10 RS RS20211247A patent/RS62430B1/sr unknown
- 2018-05-10 TW TW107115845A patent/TW201900640A/zh unknown
- 2018-05-10 CN CN201880031240.4A patent/CN110612298B/zh active Active
- 2018-05-10 HR HRP20211583TT patent/HRP20211583T1/hr unknown
- 2018-05-10 DK DK18727589.6T patent/DK3621960T3/da active
- 2018-05-10 SI SI201830426T patent/SI3621960T1/sl unknown
- 2018-05-10 AR ARP180101237A patent/AR111689A1/es unknown
- 2018-05-10 EA EA201992674A patent/EA039189B1/ru unknown
- 2018-05-10 BR BR112019023290-7A patent/BR112019023290A2/pt not_active Application Discontinuation
- 2018-05-10 MY MYPI2019006520A patent/MY200228A/en unknown
- 2018-05-10 AU AU2018265130A patent/AU2018265130B2/en not_active Expired - Fee Related
- 2018-05-10 PE PE2019002310A patent/PE20191817A1/es unknown
- 2018-05-10 WO PCT/US2018/031945 patent/WO2018209012A1/en not_active Ceased
- 2018-05-10 ES ES18727589T patent/ES2889926T3/es active Active
- 2018-05-10 US US16/612,478 patent/US10829496B2/en active Active
- 2018-05-10 PL PL18727589T patent/PL3621960T3/pl unknown
- 2018-05-10 JP JP2019561740A patent/JP7154229B2/ja active Active
- 2018-05-10 KR KR1020197036216A patent/KR102604900B1/ko active Active
- 2018-05-10 CA CA3062602A patent/CA3062602A1/en active Pending
- 2018-05-10 SM SM20210568T patent/SMT202100568T1/it unknown
-
2019
- 2019-11-07 IL IL270494A patent/IL270494B/en unknown
- 2019-11-07 CL CL2019003198A patent/CL2019003198A1/es unknown
- 2019-11-07 CO CONC2019/0012494A patent/CO2019012494A2/es unknown
-
2021
- 2021-10-07 CY CY20211100874T patent/CY1124552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124552T1 (el) | Θειενοπυριδινες και βενζοθειοφαινια χρησιμα ως αναστολεις irak4 | |
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1124496T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1120834T1 (el) | Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1 | |
| CY1124187T1 (el) | Ετεροκυκλικα αμιδια ως αναστολεις κινασης | |
| CY1124055T1 (el) | Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες | |
| CY1122821T1 (el) | Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2 | |
| CY1123645T1 (el) | Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα | |
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| CY1124798T1 (el) | Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων | |
| ECSP21060240A (es) | Inhibidores de la pcsk9 y métodos de uso de los mismos | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
| CY1125230T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CO2018008761A2 (es) | Derivados de maitansinoide, conjugados de los mismos métodos de uso | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| MA51290A (fr) | Nouvelles pyridopyrimidinones à substitution benzylamino et dérivés à utiliser en tant qu'inhibiteurs de sos1 | |
| MX383880B (es) | Inhibidores de ectonucleotidasa y metodos de uso de los mismos. | |
| MX2019007416A (es) | Derivados de benzooxazol como inmunomoduladores. | |
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| PE20210452A1 (es) | Inhibidores de la arginasa | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201791563A1 (ru) | Замещенные нуклеозидные производные, полезные в качестве агентов против рака |